Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma

References

• Kumar S. Multiple myeloma – current issues and controversies. Cancer Treat Rev 2010;36(2S):S3-11
   Google Scholar
• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49(6):1374-403
   PubMed Web of Science ®Google Scholar
• EER Stat Fact Sheets: Myeloma, 2004–2010. Available from: http://seer.cancer.gov/statfacts/html/mulmy.html [Last accessed 25 August 2014]
   Google Scholar
• Falco P, Bringhen S, Avonto I, et al. Melphalan and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther 2007;7(7):945-57
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar V, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111(5):2516-20
   PubMed Web of Science ®Google Scholar
• Anderson KC, Alsina M, Bensinger W, et al. Multiple myeloma: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2011;9:1146-83
   PubMed Web of Science ®Google Scholar
• Ludwig H, Avet-Loiseau H, Bladé J, et al. European perspective on multiple myeloma treatment strategies: update following recent congresses. Oncologist 2012;17(5):592-606
   PubMed Web of Science ®Google Scholar
• Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370(9594):1209-18
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357(21):2133-42
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357(21):2123-32
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352(24):2487-98
   PubMed Web of Science ®Google Scholar
• Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110(10):3557-60
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359(9):906-17
   PubMed Web of Science ®Google Scholar
• Gras J. Pomalidomide for patients with multiple myeloma. Drugs Today (Barc) 2013;49(9):555-62
   PubMed Web of Science ®Google Scholar
• Celgene. Thalomid (thalidomide) capsules [prescribing information]. Available from: www.thalomid.com/thalomid_pi.aspx [Last accessed 30 March 2015]
   Google Scholar
• Celgene. Revlimid (lenalidomide) capsules [prescribing information]. Available from: www.celgene.com/content/uploads/revlimid_full_prescribing_info.pdf [Last accessed 30 March 2015]
   Google Scholar
• Millennium Pharmaceuticals. Velcade (bortezomib) for injection [prescribing information]. Available from: www.velcade.com/Files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf [Last accessed 30 March 2015]
   Google Scholar
• Onyx Pharmaceuticals. Kyprolis (carfilzomib) for injection [prescribing information]. Available from: www.kyprolis.com/prescribing-information [Last accessed 30 March 2015]
   Google Scholar
• Celgene. Pomalyst (pomalidomide) capsules [prescribing information]. Available from: www.pomalyst.com/wp-content/uploads/2013/08/prescribing_information.pdf [Last accessed 30 March 2015]
   Google Scholar
• Cavallo F, Hardan I, Gay F, et al. Lenalidomide maintenance significantly reduces the risk of progression in newly diagnosed young multiple myeloma patients enrolled in RV-MM-PI-209 trial. Haematologica 2012;97(suppl 1); abstract 1142
   Google Scholar
• Bringhen S, Mateos MV, Zweegman S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica 2013;98(6):980-7
   PubMed Web of Science ®Google Scholar
• Wang TF, Ahluwalia R, Fiala MA, et al. The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide. Leuk Lymphoma 2014;55(2):337-41
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26(1):149-57
   PubMed Web of Science ®Google Scholar
• Palumbo A, Mina R. Management of older adults with multiple myeloma. Blood Rev 2013;27(3):133-42
   PubMed Web of Science ®Google Scholar
• Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget 2013;4(12):2186-207
   PubMed Web of Science ®Google Scholar
• Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007;138(5):563-79
   PubMed Web of Science ®Google Scholar
• Kellner J, Liu B, Kang Y, Li Z. Fact or fiction–identifying the elusive multiple myeloma stem cell. J Hematol Oncol 2013;6:91
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al.; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372(2):142-52
   PubMed Web of Science ®Google Scholar
• Mentlik JA, Cohen AD, Campbell KS. Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol 2013;4:481
   PubMed Web of Science ®Google Scholar
• Rossi M, Botta C, Correale P, et al. Immunologic microenvironment and personalized treatment in multiple myeloma. Expert Opin Biol Ther 2013;13(Suppl 1):S83-93
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavallo F. Have drug combinations supplanted stem cell transplantation in myeloma? Blood 2012;120(24):4692-8
   PubMed Web of Science ®Google Scholar
• Teh BW, Harrison SJ, Pellegrini M, et al. Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection. Blood Rev 2014;28(2):75-86
   PubMed Web of Science ®Google Scholar
• Feyler S, Selby PJ, Cook G. Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM). Blood Rev 2013;27(3):155-64
   PubMed Web of Science ®Google Scholar
• Yi Q. Novel immunotherapies. Cancer J 2009;15(6):502-10
   PubMed Web of Science ®Google Scholar
• Veillette A. SLAM-family receptors: immune regulators with or without SAP-family adaptors. Cold Spring Harb Perspect Biol 2010;2(3):a002469
   Web of Science ®Google Scholar
• Bouchon A, Cella M, Grierson HL, et al. Cutting edge: activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol 2001;167(10): 5517-21
   Google Scholar
• Cruz-Munoz ME, Dong Z, Shi X, et al. Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function. Nat Immunol 2009;10(3):297-305
   PubMed Web of Science ®Google Scholar
• Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother 2013;62(12):1841-9
   PubMed Web of Science ®Google Scholar
• Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008;14(9):2775-84
   PubMed Web of Science ®Google Scholar
• Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008;112(4):1329-37
   PubMed Web of Science ®Google Scholar
• Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol 2013;88(1):168-77
   PubMed Web of Science ®Google Scholar
• Benson DMJr, Byrd JC. CS1-directed monoclonal antibody therapy for multiple myeloma. J Clin Oncol 2012;30(16):2013-15
   PubMed Web of Science ®Google Scholar
• Balasa B, Yun R, Belmar NA, et al. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways. Cancer Immunol Immunother 2015;64(1):61-73
   PubMed Web of Science ®Google Scholar
• Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012;120(3):552-9
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012;30(16):1960-5
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012;30(16):1953-9
   PubMed Web of Science ®Google Scholar
• Richardson PG, Jagannath S, Moreau P, et al. Final results for the 1703 phase 1b/2 study of elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood 2014;124(21):302
   Google Scholar
• Lonial S, Jagannath S, Moreau P, et al. Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): updated Ph II results and Ph I/II long-term safety. J Clin Oncol 2013;31(Suppl):abstract 8542
   Google Scholar
• Rutella S, Locatelli F. Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes. Clin Dev Immunol 2012;2012:196063
   PubMedGoogle Scholar
• Godfrey J, Benson DMJr. The role of natural killer cells in immunity against multiple myeloma. Leuk Lymphoma 2012;53(9):1666-76
   PubMed Web of Science ®Google Scholar
• Görgün GT, Whitehill G, Anderson JL, et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013;121(15):2975-87
   PubMed Web of Science ®Google Scholar
• Chou T. Multiple myeloma: recent progress in diagnosis and treatment. J Clin Exp Hematop 2012;52(3):149-59
   PubMedGoogle Scholar
• Cives M, Simone V, Brunetti O, et al. Novel lenalidomide-based combinations for treatment of multiple myeloma. Crit Rev Oncol Hematol 2013;85(1):9-20
   PubMed Web of Science ®Google Scholar
• Hallett WH, Ames E, Motarjemi M, et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol 2008;180(1):163-70
   PubMed Web of Science ®Google Scholar
• Shi J, Tricot G, Garg T, et al. Bortezomib down-regulates the cell surface expression of HLA class I and enhances natural killer cell mediated lysis of myeloma. Blood 2008;111(3):1309-17
   PubMed Web of Science ®Google Scholar
• Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012;120(5):947-59
   PubMed Web of Science ®Google Scholar
• Moreau P, Richardson PG, Jakubowiak AJ, et al. A randomized phase 2 study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma. J Clin Oncol 2012;30(Suppl):abstract 8020
   Google Scholar
• van Rhee F, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther 2009;8(9):2616-24
   PubMed Web of Science ®Google Scholar
• Benson DMJr, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010;116(13):2286-94
   PubMed Web of Science ®Google Scholar
• Hallett WH, Jing W, Drobyski WR, Johnson BD. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant 2011;17(8):1133-45
   PubMed Web of Science ®Google Scholar
• Murillo O, Arina A, Hervas-Stubbs S, et al. Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res 2008;14(21):6895-906
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Weiskopf K, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012;122(3):1066-75
   PubMed Web of Science ®Google Scholar
• Benson DMJr, Hofmeister CC, Padmanabhan S, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012;120(22):4324-33
   PubMed Web of Science ®Google Scholar
• Bonanno G, Mariotti A, Procoli A, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. J Transl Med 2012;10:247
   PubMed Web of Science ®Google Scholar
• Richardson PG, Jagannath S, Moreau P, et al. Final results for the 1703 phase 1b/2 study of elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Presented at: 56th Annual Meeting of the American Society of Hematology (ASH); San Francisco, USA; December 6-9, 2014; Oral presentation 302: abstract 202
   Google Scholar
• Jagannath S, Lonial S, Parli T, et al. Elotuzumab-associated infusion reactions: incidence and management. Haematologica 2012;97(s1):605 [abstract 1524]
   Google Scholar
• Usmani SZ, Hoering A, Sexton R, et al. SWOG 1211: A randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM). J Clin Oncol 2014;32(Suppl 5s):abstract TPS8624
   Google Scholar
• Berdeja J, Jagannath S, Zonder J, et al. Pharmacokinetics and safety of elotuzumab in combination with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal function: results of a phase 1b study. Blood 2014;124(21):2119
   Google Scholar
• Mateos MV, Granell M, Oriol Rocafiguera A, et al. A phase II single-arm safety study of Elotuzumab in combination with thalidomide and low dose dexamethasone in patients with relapsed and/or refractory multiple myeloma (CA204-010). Haematologica 2014;99(s1):364-5
   Google Scholar
• Jakubowiak AJ, White D, Moreau P, et al. A phase II randomized study of bortezomib/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma. J Clin Oncol 2012;30(Suppl):abstract TPS8114
   Google Scholar
• Dimopoulos MA, Facon T, Richardson PGG, et al. ELOQUENT-1: a phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006). J Clin Oncol 2012;30(Suppl):abstract TPS8113
   Google Scholar
• Lonial S, Richardson PGG, Moreau P, et al. ELOQUENT-2: a phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in relapsed or refractory multiple myeloma (CA204-004). J Clin Oncol 2012;30(Suppl):abstract TPS8112
   Google Scholar
• Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma (ELOQUENT - 2). Available from: https://clinicaltrials.gov/ct2/show/NCT01239797
   Google Scholar
• Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1). Available from: https://clinicaltrials.gov/ct2/show/NCT01335399
   Google Scholar
• Danylesko I, Beider K, Shimoni A, Nagler A. Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol 2012;2012:753407
   PubMedGoogle Scholar
• Rosenblatt J, Avivi I, Vasir B, et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013;19(13):3640-8
   PubMed Web of Science ®Google Scholar
• Pyzer AR, Avigan DE, Rosenblatt J. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies. Hum Vaccin Immunother 2014;10(11):3125-31
   PubMed Web of Science ®Google Scholar
• Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 2013;19(8):2048-60
   PubMed Web of Science ®Google Scholar
• Chu J, He S, Deng Y, et al. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin Cancer Res 2014;20(15):3989-4000
   PubMed Web of Science ®Google Scholar
• Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma. Available from: https://clinicaltrials.gov/ct2/show/NCT00425347
   Google Scholar
• A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies. Available from: https://clinicaltrials.gov/ct2/show/NCT00726869
   Google Scholar
• A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma. Available from: https://clinicaltrials.gov/ct2/show/NCT00742560
   Google Scholar
• Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma. Available from: https://clinicaltrials.gov/ct2/show/NCT01441973
   Google Scholar
• S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk. Available from: https://clinicaltrials.gov/ct2/show/NCT01668719
   Google Scholar
• Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function. Available from: https://clinicaltrials.gov/ct2/show/NCT01393964
   Google Scholar
• Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone. Available from: https://clinicaltrials.gov/ct2/show/NCT01241292
   Google Scholar
• Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. Available from: https://clinicaltrials.gov/ct2/show/NCT01632150
   Google Scholar
• Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma. Available from: https://clinicaltrials.gov/ct2/show/NCT01478048
   Google Scholar
• Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT02159365
   Google Scholar